Browse the catalogue using the navigation menu to explore further back into the database, or use the search tool to research throughout the store.

Products In Core Medical (Total Products 55, Showing: 1 -> 20)

Abatacept: the evidence for its place in the treatment of rheumatoid arthritis Our Price: £20.00 With its different mechanism of action, abatacept may be an alternative therapy for patients with an inadequate response to other arthritis therapies, especially for those patients with RA refractory to anti-TNF treatment. CLICK TO BUY ONLINE NOW! | Read full details

Adalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy Our Price: £20.00 Abbott’s Humira (adalimumab) improves signs and symptoms, inflammation, and quality of life in patients with ankylosing spondylitis, and is cost effective when used according to current guidelines. CLICK TO BUY ONLINE NOW! | Read full details

Agomelatine: the evidence for its place in the treatment of depression Our Price: £20.00 Agomelatine has good efficacy compared with standard antidepressants for the acute treatment of major depression. In published studies it had a better tolerability profile than SSRIs or SNRIs CLICK TO BUY ONLINE NOW! | Read full details

Aliskiren in hypertension: evidence for its potential therapeutic value Our Price: £20.00 This Core Evidence proof of concept review on aliskiren, the first in a new class of antihypertensives, reviews the evidence for its use in patients with mild-to-moderate hypertension. CLICK TO BUY ONLINE NOW! | Read full details

Anidulafungin: an evidence-based review of its use in invasive fungal infections Our Price: £20.00 Current evidence supports the use of anidulafungin in the management of candidemia, esophageal candidiasis, and invasive candidiasis as shown by the successful results in large multicenter trials. CLICK TO BUY ONLINE NOW! | Read full details

Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting Our Price: £20.00 Despite recent advances, CINV remains a problem for many cancer patients. Merck’s aprepitant, a novel NK1 receptor antagonist, represents a significant advance in highly and moderately emetogenic chemotherapy. CLICK TO BUY ONLINE NOW! | Read full details

Aripiprazole: the evidence of its therapeutic impact in schizophrenia Our Price: £20.00 Aripiprazole is an atypical antipsychotic suitable for first line use in patients with schizophrenia. This Core Evidence review concludes that it may be particularly useful where tolerability is an issue and in patients with negative symptoms. CLICK TO BUY ONLINE NOW! | Read full details

Arzoxifene: the evidence for its development in the management of breast cancer Our Price: £20.00 Despite early promise as the 'ideal SERM', results from phase III trials have relegated arzoxifene to research in breast cancer prevention and osteoporosis treatment CLICK TO BUY ONLINE NOW! | Read full details

Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer Our Price: £20.00 There is clear evidence that bevacizumab extends overall and progression-free survival, and improves response rates in patients with NSCLC, and could have a significant clinical impact according to this Core Evidence review. CLICK TO BUY ONLINE NOW! | Read full details

Bortezomib: the evidence of its clinical impact in multiple myeloma Our Price: £20.00 This Core Evidence review presents the evidence supporting bortezomib as a valuable treatment option in patients with multiple myeloma. It is the first and only single agent with evidence of a survival advantage in relapsed or refractory disease. CLICK TO BUY ONLINE NOW! | Read full details

Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas Our Price: £20.00 This evidence-based review shows that capecitabine can be considered as first-line treatment in combination with gemcitabine to improve response rates and prolong survival by a small but significant margin in patients with advanced pancreatic cancer CLICK TO BUY ONLINE NOW! | Read full details

Certolizumab pegol: an evidence-based review of its place in the treatment of Crohn's disease Our Price: £20.00 Available studies suggest that certolizumab pegol has the potential to achieve and maintain clinical response and remission in moderate to severe Crohn’s disease, and to improve quality of life CLICK TO BUY ONLINE NOW! | Read full details

Ciclesonide in persistent asthma: the evidence of its therapeutic value Our Price: £20.00 The clear evidence for the efficacy and safety of ALTANA’s airway-activated corticosteroid ciclesonide in asthma is evaluated in this Core Evidence review. The lack of effect on adrenal function confers a clinical benefit, particularly in children. CLICK TO BUY ONLINE NOW! | Read full details

Dasatinib: the emerging evidence of its potential in the treatment of chronic myeloid leukemia Our Price: £20.00 This Core Evidence emerging therapy review of Dasatinib evaluates the emerging evidence of its potential in the treatment of chronic myeloid leukemia. CLICK TO BUY ONLINE NOW! | Read full details

Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes Our Price: £20.00 This Core Evidence Clinical Impact Review evaluates the clinical impact of donepezil by assessing randomized controlled and open-label naturalistic trials, as well as observational studies. CLICK TO BUY ONLINE NOW! | Read full details

Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia Our Price: £20.00 Dutasteride reduces prostate size in men with BPH according to this Core Evidence clinical impact review, thus providing symptom relief and avoiding the need for surgery. CLICK TO BUY ONLINE NOW! | Read full details

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia Our Price: £20.00 GSK’s eltrombopag appears to offer a promising treatment for idiopathic thrombocytopenia purpura, a condition currently without safe options for sustained responses. This Core Evidence article reviews the early evidence. CLICK TO BUY ONLINE NOW! | Read full details

Eplerenone: the evidence for its place in the treatment of heart failure after myocardial infarction Our Price: £20.00 This Core Evidence place in therapy review concludes that there is clear evidence of a survival benefit and reduced cardiovascular morbidity and mortality when eplerenone is added to standard treatment in patients with heart failure following CLICK TO BUY ONLINE NOW! | Read full details

Eptifibatide: the evidence for its role in the management of acute coronary syndromes Our Price: £20.00 This review of the Gp IIb/IIIa inhibitor eptifibatide shows why it has gained widespread acceptance as an adjunct to standard anticoagulation therapy in patients with acute coronary syndromes. CLICK TO BUY ONLINE NOW! | Read full details

Eritoran: the evidence of its therapeutic potential in sepsis Our Price: £20.00 Eritoran is an exciting potential therapeutic option for management of sepsis with a reasonable safety and tolerability profile that must be validated by rigorous randomized clinical trials CLICK TO BUY ONLINE NOW! | Read full details

1 2 3 [Next]